Valuation: Evofem Biosciences, Inc.

Market Cap 1.06M 927K 852K 794K 1.51M 101M 1.53M 10.23M 3.98M 49.62M 3.98M 3.89M 171M P/E 2024
-0.08x
P/E 2025 26.7x
Enterprise Value 55.48M 48.5M 44.57M 41.54M 78.8M 5.28B 79.99M 535M 208M 2.6B 208M 204M 8.95B EV / Sales 2024
2.43x
EV / Sales 2025 2.76x
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
1 day-9.09%
1 week-2.44%
3 months-3.61%
6 months-15.79%
Current year-15.79%
1 week 0.01
Extreme 0.0077
0.01
1 month 0.01
Extreme 0.007
0.01
Current year 0
Extreme 0.0008
0.01
1 year 0
Extreme 0.0008
0.02
3 years 0
Extreme 0.0008
1.4
5 years 0
Extreme 0.0008
1,987.5
10 years 0
Extreme 0.0008
23,549.99
Manager TitleAgeSince
Chief Executive Officer 57 01/01/2018
Director of Finance/CFO 49 13/04/2023
Chief Operating Officer - -
Director TitleAgeSince
Chairman 57 -
Director/Board Member 67 01/01/2018
Director/Board Member 58 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
12/01/24Sell

Chief Financial Officer

104 0.0010%
21/12/23Sell

Director

10 0.0001%
13/04/23Other

Chief Financial Officer

13,000 0.0107%
Change 5-day change 1-year change 3-year change Capi.($)
-9.09%-2.44%-20.00%-99.00% 1.06M
+1.86%+0.48%+55.50%+163.08% 1,082B
+3.57%+3.29%+68.60%+61.03% 633B
+3.99%+3.05%+37.93%+93.37% 461B
+3.86%+1.64%+32.57%+24.89% 338B
-0.56%+0.96%+41.67%+39.35% 299B
-0.08%+1.30%+32.15%+44.48% 291B
-1.54%+2.81%-25.35%-39.61% 222B
+3.55%+4.41%+25.45%+66.28% 202B
+4.21%+2.65%+17.47%+71.11% 163B
Average +0.98%+3.29%+26.60%+42.50% 369.24B
Weighted average by Cap. +2.25%+5.53%+42.31%+83.31%

Financials

2024 2025
Net sales 19.36M 16.93M 15.56M 14.5M 27.5M 1.84B 27.92M 187M 72.6M 906M 72.68M 71.12M 3.12B 20.18M 17.64M 16.21M 15.11M 28.67M 1.92B 29.1M 195M 75.67M 945M 75.76M 74.13M 3.26B
Net income -8.86M -7.75M -7.12M -6.63M -12.58M -844M -12.78M -85.45M -33.22M -415M -33.26M -32.54M -1.43B 391K 342K 314K 293K 555K 37.23M 564K 3.77M 1.47M 18.3M 1.47M 1.44M 63.06M
Net Debt 45.84M 40.07M 36.83M 34.33M 65.11M 4.36B 66.1M 442M 172M 2.15B 172M 168M 7.39B 54.42M 47.57M 43.72M 40.75M 77.29M 5.18B 78.46M 525M 204M 2.55B 204M 200M 8.78B
Logo Evofem Biosciences, Inc.
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing its products to address unmet needs in women’s sexual and reproductive health. The Company’s first approved product, PHEXXI (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of over 12 pre-filled applicators and is applied 0-60 minutes before each act of intercourse. PHEXXI is a gel that works to prevent pregnancy without the use of hormones. PHEXXI prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Using the PHEXXI telehealth platform, women can directly meet with a health care provider to determine their eligibility for a PHEXXI prescription. The Company also commercialized SOLOSEC (secnidazole) 2g oral granules, an antibiotic for the treatment of two sexual health diseases such as bacterial vaginosis and trichomoniasis.
Employees
29
Date Price Change Volume
02/07/26 $0.008000 -9.09% 614,709
01/07/26 $0.008800 +10.41% 2,247,181
30/06/26 $0.007970 -3.80% 10,231
29/06/26 $0.008285 +1.04% 32,417
26/06/26 $0.008200 -6.02% 278,264

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVFM Stock